Although
chemotherapy has an important function in the treatment of most solid tumours, its clinical applications are limited by severe side effects such as nephrotoxicity, hepatotoxicity,
ototoxicity and neurotoxicity. Recently, a growing amount of attention has been focused on the investigation of the effects of chemopreventive agents on the inhibition of
cancer cell growth and toxicity in combination with chemotherapeutics. The aim of this study was to determine whether
licochalcone A (LCA) has the potential to serve as a beneficial supplement during
cisplatin chemotherapy. We found that the administration of LCA alone significantly inhibited the size of the solid tumours in CT-26 cell-inoculated Balb/c mice, without any detectable induction of nephrotoxicity, hepatotoxicity and oxidative stress. LCA also suppressed cell proliferation by reducing
DNA synthesis of CT-26 murine
colon cancer cells in a dose-dependent manner. LCA did not affect the therapeutic efficacy of
cisplatin. Furthermore, LCA inhibited the
cisplatin-induced kidney damage characterized by increases in the serum
creatinine and blood
urea nitrogen, as well as the
cisplatin-induced liver damage characterized by increases in the serum
alanine aminotransferase and
aspartate aminotransferase. The repeated
oral administration of LCA prior to
cisplatin treatment exerted a preventive effect on the
cisplatin-mediated increases in the serum
nitric oxide and the tissue lipid peroxidation levels, and recovered the depleted
reduced glutathione levels in the tissues. These results suggest that supplementation with LCA may be beneficial in counteracting the side effects of
cisplatin therapy in
cancer patients.